VERICEL CORPORATION Cost of Revenue
VERICEL CORPORATION (VCEL) reported Cost of Revenue of $21.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-30
- VERICEL CORPORATION cost of goods and services sold for the quarter ending 2026-06-30 was $21.05M, a 26.63% increase year-over-year.
- VERICEL CORPORATION cost of goods and services sold for the quarter ending 2026-03-31 was $19.16M, a 17.36% increase year-over-year.
- VERICEL CORPORATION cost of goods and services sold for the quarter ending 2025-12-31 was $19.79M, a 17.26% increase year-over-year.
- VERICEL CORPORATION cost of goods and services sold for the quarter ending 2025-09-30 was $17.92M, a 10.25% increase year-over-year.
- VERICEL CORPORATION cost of goods and services sold for fiscal 2025 was $70.66M, a 8.51% increase from fiscal 2024.
- VERICEL CORPORATION cost of goods and services sold for fiscal 2024 was $65.12M, a 5.13% increase from fiscal 2023.
- VERICEL CORPORATION cost of goods and services sold for fiscal 2023 was $61.94M, a 13.49% increase from fiscal 2022.
- VERICEL CORPORATION cost of goods and services sold for fiscal 2022 was $54.58M, a 8.81% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.05M 10-Q · filed 2026-07-30 | $40.21M 10-Q · filed 2026-07-30 | $60.00M derived: sum of 3 quarters · filed 2026-07-30 | $77.92M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $19.16M 10-Q · filed 2026-05-07 | $38.95M derived: sum of 2 quarters · filed 2026-05-07 | $56.87M derived: sum of 3 quarters · filed 2026-05-07 | $73.49M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $19.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.71M derived: sum of 2 quarters · filed 2026-02-26 | $54.34M derived: sum of 3 quarters · filed 2026-07-30 | $70.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $17.92M 10-Q · filed 2025-11-06 | $34.55M derived: sum of 2 quarters · filed 2026-07-30 | $50.87M 10-Q · filed 2025-11-06 | $67.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $16.63M 10-Q · filed 2026-07-30 | $32.95M 10-Q · filed 2026-07-30 | $49.83M derived: sum of 3 quarters · filed 2026-07-30 | $66.08M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $16.32M 10-Q · filed 2026-05-07 | $33.20M derived: sum of 2 quarters · filed 2026-05-07 | $49.45M derived: sum of 3 quarters · filed 2026-05-07 | $65.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.13M derived: sum of 2 quarters · filed 2026-02-26 | $49.19M derived: sum of 3 quarters · filed 2026-02-26 | $65.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.25M 10-Q · filed 2025-11-06 | $32.31M derived: sum of 2 quarters · filed 2025-11-06 | $48.24M 10-Q · filed 2025-11-06 | $64.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $16.06M 10-Q · filed 2025-07-31 | $31.99M 10-Q · filed 2025-07-31 | $48.48M derived: sum of 3 quarters · filed 2026-02-26 | $63.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $15.93M 10-Q · filed 2025-05-08 | $32.42M derived: sum of 2 quarters · filed 2026-02-26 | $47.39M derived: sum of 3 quarters · filed 2026-02-26 | $63.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.46M derived: sum of 2 quarters · filed 2026-02-26 | $47.44M derived: sum of 3 quarters · filed 2026-02-26 | $61.94M 10-K · filed 2026-02-26 |
| 2023-09-30 | $14.97M 10-Q · filed 2024-11-07 | $30.95M derived: sum of 2 quarters · filed 2024-11-07 | $45.45M 10-Q · filed 2024-11-07 | $59.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $15.98M 10-Q · filed 2024-08-01 | $30.48M 10-Q · filed 2024-08-01 | $44.92M derived: sum of 3 quarters · filed 2025-02-27 | $58.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $14.50M 10-Q · filed 2024-05-08 | $28.94M derived: sum of 2 quarters · filed 2025-02-27 | $42.26M derived: sum of 3 quarters · filed 2025-02-27 | $56.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $27.76M derived: sum of 2 quarters · filed 2025-02-27 | $41.95M derived: sum of 3 quarters · filed 2025-02-27 | $54.58M 10-K · filed 2025-02-27 |
| 2022-09-30 | $13.32M 10-Q · filed 2023-11-08 | $27.51M derived: sum of 2 quarters · filed 2023-11-08 | $40.13M 10-Q · filed 2023-11-08 | $53.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.19M 10-Q · filed 2023-08-02 | $26.81M 10-Q · filed 2023-08-02 | $40.37M derived: sum of 3 quarters · filed 2024-02-29 | $52.78M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $12.62M 10-Q · filed 2023-05-10 | $26.18M derived: sum of 2 quarters · filed 2024-02-29 | $38.59M derived: sum of 3 quarters · filed 2024-02-29 | $51.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $13.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $25.97M derived: sum of 2 quarters · filed 2024-02-29 | $38.58M derived: sum of 3 quarters · filed 2024-02-29 | $50.16M 10-K · filed 2024-02-29 |
| 2021-09-30 | $12.41M 10-Q · filed 2022-11-09 | $25.02M derived: sum of 2 quarters · filed 2022-11-09 | $36.60M 10-Q · filed 2022-11-09 | $48.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $12.61M 10-Q · filed 2022-08-03 | $24.19M 10-Q · filed 2022-08-03 | $35.77M derived: sum of 3 quarters · filed 2023-02-23 | $45.56M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $11.58M 10-Q · filed 2022-05-04 | $23.16M derived: sum of 2 quarters · filed 2023-02-23 | $32.95M derived: sum of 3 quarters · filed 2023-02-23 | $41.61M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $11.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $21.37M derived: sum of 2 quarters · filed 2023-02-23 | $30.03M derived: sum of 3 quarters · filed 2023-02-23 | $39.95M 10-K · filed 2023-02-23 |
| 2020-09-30 | $9.79M 10-Q · filed 2021-11-09 | $18.45M derived: sum of 2 quarters · filed 2021-11-09 | $28.37M 10-Q · filed 2021-11-09 | $38.95M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $8.66M 10-Q · filed 2021-08-04 | $18.58M 10-Q · filed 2021-08-04 | $29.17M derived: sum of 3 quarters · filed 2022-02-24 | $38.49M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $9.92M 10-Q · filed 2021-05-05 | $20.51M derived: sum of 2 quarters · filed 2022-02-24 | $29.83M derived: sum of 3 quarters · filed 2022-02-24 | $38.85M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $19.91M derived: sum of 2 quarters · filed 2022-02-24 | $28.93M derived: sum of 3 quarters · filed 2022-02-24 | $37.57M 10-K · filed 2022-02-24 |
| 2019-09-30 | $9.32M 10-Q · filed 2020-11-05 | $18.35M derived: sum of 2 quarters · filed 2020-11-05 | $26.99M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $9.02M 10-Q · filed 2020-08-05 | $17.66M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $8.64M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $32.16M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $30.35M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $28.31M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |